Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival
Authors
Keywords
Pancreatic cancer, Chemotherapy, Gemcitabine refractory, Fixed dose rate infusion, S-1, Inflammation-based prognostic score, Glasgow prognostic score
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 75, Issue 3, Pages 457-464
Publisher
Springer Nature
Online
2014-12-29
DOI
10.1007/s00280-014-2665-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy
- (2014) Min Geun Lee et al. CHEMOTHERAPY
- A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer
- (2013) Naminatsu Takahara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
- (2013) Hideki Ueno et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Glasgow Prognostic Score as a Predictor of Survival in Patients with Potentially Resectable Pancreatic Adenocarcinoma
- (2012) Marco La Torre et al. ANNALS OF SURGICAL ONCOLOGY
- An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study
- (2011) M J Proctor et al. BRITISH JOURNAL OF CANCER
- Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
- (2011) Chigusa Morizane et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
- (2011) Elias Assaf et al. ONCOLOGY
- Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
- (2010) Kentaro Sudo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Glasgow Prognostic Score Is a Good Predictor of Treatment Outcome in Patients with Unresectable Pancreatic Cancer
- (2010) Mitsugi Shimoda et al. CHEMOTHERAPY
- S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure
- (2010) A. Todaka et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
- (2008) Chigusa Morizane et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy
- (2008) T. Tanaka et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now